-+ 0.00%
-+ 0.00%
-+ 0.00%

Sinovac regains Nasdaq listing compliance after filing annual report

PUBT·06/15/2026 10:00:42
Listen to the news
Sinovac regains Nasdaq listing compliance after filing annual report
  • Sinovac regained compliance with Nasdaq Listing Rule 5250(c)(1) following the filing of its 2025 annual report on Form 20-F.
  • Nasdaq canceled a requested hearings panel session after confirming the company met the Global Market’s listing requirements.
  • The stock remains under a mandatory panel monitor through May 20, 2027 under Listing Rule 5815(d)(4)(B).


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sinovac Biotech Ltd. published the original content used to generate this news brief via Business Wire (Ref. ID: 202606150600BIZWIRE_USPR_____20260615_BW800954) on June 15, 2026, and is solely responsible for the information contained therein.